Literature DB >> 25724033

An algorithmic approach to sellar region masses.

B K Kleinschmidt-DeMasters1, M B S Lopes, Richard A Prayson.   

Abstract

CONTEXT: Most sellar region masses (85%-90%) are pituitary adenomas; however, other neoplasms or even inflammatory or cystic nonneoplastic lesions may occasionally be encountered in this location. A practical, non-electron-microscopically based approach is essential for the daily practice of diagnosing and subclassifying adenomatous and nonadenomatous sellar region lesions.
OBJECTIVE: To provide an algorithmic approach to sellar region masses for the pathologist and to formulate a cost-effective, limited panel of stains and immunostains that can be used in daily practice at most small to medium-sized centers.
DESIGN: Pool collective experience of 3 neuropathologists practicing at academic medical centers with expertise in diagnosis and treatment of sellar region masses to craft a single-page algorithmic diagram and to liberally illustrate the range of lesions present in the sellar region.
RESULTS: After formulating a differential diagnosis, the general pathologist can generate a confident final diagnosis of adenoma using 1 histochemical (reticulin) and 1 immunohistochemical (synaptophysin) stain, supplemented by 5 immunohistochemical stains (CAM5.2, follicle-stimulating hormone, growth hormone, prolactin, and adrenocorticotropic hormone), which provide subtyping of the adenoma in the overwhelming majority of examples. CAM5.2 and clinical information further help identify clinically aggressive variants such as sparsely granulated growth hormone adenomas and silent adrenocorticotropic hormone adenomas, respectively. MIB-1, thyroid transcription factor 1, and S-100 protein can be of further assistance in select cases where increased mitotic activity or possible nonadenomatous spindle cell lesions are suspected.
CONCLUSIONS: Adenomas, normal anterior or posterior gland, and nonadenomatous masses can be easily diagnosed in a nontertiary pathology laboratory setting.

Entities:  

Mesh:

Year:  2015        PMID: 25724033     DOI: 10.5858/arpa.2014-0020-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  5 in total

Review 1.  A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal.

Authors:  C Villa; A Vasiljevic; M L Jaffrain-Rea; O Ansorge; S Asioli; V Barresi; L Chinezu; M P Gardiman; A Lania; A M Lapshina; L Poliani; L Reiniger; A Righi; W Saeger; J Soukup; M Theodoropoulou; S Uccella; J Trouillas; F Roncaroli
Journal:  Virchows Arch       Date:  2019-10-02       Impact factor: 4.064

2.  Collision sellar lesions: coexistence of pituitary adenoma and Rathke cleft cyst-a single-center experience.

Authors:  Annelise de Almeida Verdolin; Elisa Baranski Lamback; Nina Ventura; André Guasti; Paulo José da Mata Pereira; Mônica R Gadelha; Leila Chimelli
Journal:  Endocrine       Date:  2019-12-04       Impact factor: 3.633

3.  Xanthomatous Hypophysitis Is Associated with Ruptured Rathke's Cleft Cyst.

Authors:  Kai Duan; Sylvia L Asa; Daniel Winer; Zadeh Gelareh; Fred Gentili; Ozgur Mete
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 4.  Aggressive nonfunctioning pituitary neuroendocrine tumors.

Authors:  Sérgio Portovedo; Leonardo Vieira Neto; Christina Maeda Takiya; Leandro Miranda-Alves; Paula Soares; Denise Pires de Carvalho
Journal:  Brain Tumor Pathol       Date:  2022-06-20       Impact factor: 3.154

5.  USP8 Mutations in Pituitary Cushing Adenomas-Targeted Analysis by Next-Generation Sequencing.

Authors:  Cora Ballmann; Anne Thiel; Hannah E Korah; Anna-Carinna Reis; Wolfgang Saeger; Stefanie Stepanow; Karl Köhrer; Guido Reifenberger; Christiane B Knobbe-Thomsen; Ulrich J Knappe; Ute I Scholl
Journal:  J Endocr Soc       Date:  2018-02-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.